Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244006 | 0.82 | CHRM2 (0.48) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL8273018 | 0.82 | CHRM2 (0.48) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL1003701 | 0.82 | CTSB (0.41) | CHRM2CHRM1CHRM4 | |
| SCHEMBL2244519 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL8271444 | 0.78 | CHRM2 (0.55) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL2249606 | 0.78 | CHRM2 (0.51) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL2243961 | 0.78 | CHRM2 (0.55) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL27680766 | 0.77 | CHRM2 (0.50) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL2251211 | 0.75 | CHRM2 (0.50) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL2247465 | 0.73 | CHRM2 (0.49) | CHRM2CHRM1CHRM3CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844032-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-07-13 | — | — | EP | claimed |
| US-7868009-B2 | N-hydroxyamide derivatives and use thereof | Merck Serono, S.A. (CH) | 2011-01-11 | — | — | US | claimed |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO S.A. (CH) | 2008-04-17 | — | — | US | claimed |
| US-8198280-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-06-12 | — | — | US | disclosed |
| US-8198280-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-06-12 | — | — | US | disclosed |
| US-8198280-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-06-12 | — | — | US | disclosed |
| EP-1844032-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-07-13 | — | — | EP | disclosed |
| EP-1844032-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-07-13 | — | — | EP | disclosed |
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-7868009-B2 | N-hydroxyamide derivatives and use thereof | Merck Serono, S.A. (CH) | 2011-01-11 | — | — | US | disclosed |
| US-7868009-B2 | N-hydroxyamide derivatives and use thereof | Merck Serono, S.A. (CH) | 2011-01-11 | — | — | US | disclosed |
| US-7868009-B2 | N-hydroxyamide derivatives and use thereof | Merck Serono, S.A. (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO S.A. (CH) | 2008-04-17 | — | — | US | disclosed |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO S.A. (CH) | 2008-04-17 | — | — | US | disclosed |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO S.A. (CH) | 2008-04-17 | — | — | US | disclosed |
| EP-1844032-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079653-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006079653-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | CHRM2 531/4885CHRM1 767/4885CHRM3 667/4885 |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | HNMT, ALOX5, HCAR2 | CHRM2 801/4885CHRM1 920/4885CHRM3 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.